Ortho Pharmaceutical Corporation

Janssen Pharmaceutica Nv

Ortho-mcneil Pharmaceutical Corp.

Basf Aktiengesellschaft

Other

Ethicon, Gmbh

Orapharma, Inc.

Michael P Wachter

William V Murray

Scott A Beers

Mingde Xia

Fina Liotta

Michael P Ferro

Elizabeth A Malloy

Meng Pan

Huajun Lu

Peter J Connolly

Stanley Charles Bell

Bernd Janssen

Robert H Chen

Ramesh M Kanojia

Hans-Heiner Wuest

Zoltan G Hajos

Wei Wu

Charles F Schwender

Victor T Bandurco

Bharat Lagu

Donald S Karanewsky

Zhihua Sui

Mark J Macielag

Kenneth C Rupert

David Wasserman

Joseph A Settepani

Charles C Versfelt

Praful Lalan

Mingde Xie

Hans H Wuest

Dowon Hahn

Lu Huajun

Xia Mingde

Pan Meng

This invention is directed to a hexahydro-cycloheptapyrazole cannabinoid modulator compound of formula (I): and a method for use in treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease.

Hexahydro-cycloheptapyrazole cannabinoid modulators

This invention is directed to a tetrahydro-cyclopentyl pyrazole cannabinoid modulator compound of formula (I): and a method for use in treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease.

Tetrahydro-cyclopentyl pyrazole cannabinoid modulators

This invention is directed to a hexahydro-cyclooctyl pyrazole cannabinoid modulator compound of formula (I): and a method for use in treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease.

Hexahydro-cyclooctyl pyrazole cannabinoid modulators

This invention is directed to a tetrahydro-1H-1,2,6-triaza-azulene cannabinoid modulator compound of formula (I): and a method for use in treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease.

Tetrahydro-1H-1,2,6-triaza-azulene cannabinoid modulators

This invention is directed to a cannabinoid modulator compound of formula (I): or a form thereof, and methods for use in treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease.

Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators

Quaternary salt compounds of Formula (I) or pharmaceutically acceptable forms thereof, which are CCR2 antagonists and are useful in preventing, treating or ameliorating CCR2 mediated inflammatory syndromes, disorders or diseases in a subject in need thereof.

Quaternary salt CCR2 antagonists

This invention is directed to a tetrahydro-2H-indazole pyrazole cannabinoid modulator compound of formula (I): or a form thereof, wherein p, R, Rand Ar are as herein described and * represents a chiral center, and a method for use in treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease.

Tetrahydro-2H-indazole pyrazole cannabinoid modulators

The invention relates to a CB modulator compound of Formula (I) or a pharmaceutically acceptable form thereof and a method for use in treating, ameliorating or preventing a CB receptor mediated syndrome, disorder or disease.

Tetrahydrothiopyrano pyrazole cannabinoid modulators

This invention is directed to acetylenic compounds as inhibitors of a nicotinamide adenine dinucleotide oxidase hydride donor useful in treating or ameliorating a reactive oxygen species mediated inflammatory disorder.

Acetylenic compounds useful in treating inflammatory disorders

This invention is directed to a tetrahydro-indazole cannabinoid modulator compound of formula I: and a method for use in treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease.

Tetrahydro-indazole cannabinoid modulators

Growing community of inventors

Bloomsbury, NJ, United States of America

Michael P Wachter